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Introduction
Cardiovascular Disease (CVD) is today the largest single contributor to global mortality and will continue to dominate mortality trends in the future. [1] Both CVD and Chronic Obstructive Pulmonary Disease (COPD) are global epidemics, each affecting in excess of 10 million patients. [1, 2] Both conditions incur significant morbidity and mortality, and present major challenges to healthcare providers. [2] Coronary Artery disease (CAD) is the most common type of heart disease and cause of heart attacks. The disease is caused by plaque building up along the inner walls of the arteries of the heart, which narrows the arteries and reduces blood flow to the heart. CAD is likely to become the most common cause of death worldwide by 2020. [3] Chronic obstructive pulmonary disease (COPD), a common preventable and treatable disease, is characterized by persistent, usually progressive airflow limitation and is associated with an enhanced chronic inflammatory response of the airways and the lung to noxious particles or gases. [2] It is now well established that Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory condition with significant extrapulmonary manifestations. [4] In patients with mild-to moderate COPD, the leading cause of morbidity and mortality is cardiovascular disease. In the Lung Health Study, which examined nearly 6,000 smokers whose FEV1 was between 55% and 90% predicted, cardiovascular diseases were the leading cause of hospitalization, accounting for nearly 50% of all hospital admissions, and the second leading cause of mortality, accounting for a quarter of all deaths. [5] Subsequent studies have confirmed that, on average, patients with COPD have two to three times the risk of hospitalization for cardiovascular conditions (including ischemic heart disease, stroke, and heart failure) compared to those patients without COPD. [6] Although COPD and CAD have common causal factors, primarily smoking, the increase of CAD in patients with COPD is independent of these known risk factors. [7] The exact mechanism linking COPD to heart disease is not yet known, but systemic inflammation, oxidative stress and hypoxemia are the major putative candidates. Of these, systemic inflammation is supported by the greatest amount of evidence.
Low grade systemic inflammation occurs in patients with clinically stable COPD and in many other chronic conditions, including CAD. Furthermore, in COPD, systemic inflammation persists after smoking cessation [8] and increases during the exacerbation of the disease. Notably, it is during exacerbations that patients with COPD have the highest risk of a cardiovascular event. [9] The aim of present study was to find the prevalencee of COPD in CAD patients and study various associated factors.
II. Materials & Methods
A cross sectional study was conducted between January 2010 to December 2012 at tertiary care hospitals and medical colleges of Mumbai, after obtaining permission from Institutional Ethical Committee (IEC). A total of 100 consecutive patients of CHD attending the Medicine OPD of the parent hospital fulfilling the inclusion and exclusion criteria were selected for study after obtaining informed consent. Spirometry was performed on all patients using an electronic spirometer: (Spida 5, Micromedical, England). The manoeuvre was explained to each subject and the best of three readings was recorded. Height was measured to the nearest centimetre and weight was recorded to the nearest kilogram. A study diagnosis of COPD was assigned using GOLD criteria: [10] Spirometric classification of chronic obstructive pulmonary disease (COPD) 
II
Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.
III
Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m). Comfortable only at rest.
IV
Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.
All the data was collected using a pre-formed, pre-tested, semi structured questionnaire and entered in MS Excel spreadsheet ver. 2007. The data was then transferred and analysed using SPSS ver. 19 software using appropriate statistical tests. P-value of < 0.05 was considered as significant.
III. Results
The mean age of study subjects was 48.3 ± 7.7 years. Out of the total 100 study subjects 44 were females and 56 were males. The overall prevalence of COPD as diagnosed using GOLD criteria was 19% (table 1) . Distribution of patients as per NYHA classification (table 2) showed 62% patients had cardiac disease, but no symptoms and no limitation in ordinary physical activity (NYHA class I). On evaluating the association of various demographic and clinical characteristics of patients with COPD (table 3), we found increasing age (> 60 years), severe cardiac abnormality (NYHA Class II/ III), diastolic dysfunction and history of smoking were significantly associated with increased risk of COPD.
IV. Discussion
The present study has shown that around one in five patients (19%) with CAD have concomitant COPD. Prior work has demonstrated that CAD and COPD co-morbidity exists at different rates. [12] [13] [14] [15] However, these studies were either retrospective or were conducted in primary care settings where the diagnoses of CAD was made on clinical grounds. [14, 15] The difference in prevalence between previous work and our study may be explained by the fact that the present study was hospital based and only diagnosed cases of CHD were taken for the study. Moreover, the present study was conducted in a developing world country where the epidemiology of CAD and COPD are likely to be different compared with those of the developed world. Nevertheless, the prevalence rate recorded in this study is high enough to warrant COPD screening of all patients with proven CAD.
Epidemiological studies have shown that the developing world will bear the brunt of the worldwide increasing incidence of CAD and CAD mortality. [16] Given these projected increases in CAD the high prevalence of COPD co-morbidity in CAD patients shown in this study will have an enormous burden in terms of disability, mortality and health expenditure in developing world countries. [12, 17, 18] This will be an add on to health budgets that are already exhausted by the load of treating and preventing endemic diseases.
Diastolic dysfunction on 2 D-Echo was found to be associated with COPD. Similar association was found in various other studies. [19] [20] [21] Our study identified three main risk factors for COPD and CAD co-morbidity: increasing age, smoking and advanced cardiac dysfunction. Community based studies have shown that the prevalence of COPD increases with increasing age and it is significantly associated with history of smoking. [22] [23] [24] [25] It was, therefore, not surprising to find significantly more COPD in older patients and smokers. In a study Ahmed AE et al. [27] found the prevalence of COPD and CAD as co-morbidity in smokers to be 39% which support the findings of the present study.
Severity of cardiac dysfunction was found to be associated with development of COPD. Similar observations were made by Patel AR et al. [27] who studied the the impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. They conclude that patients with COPD and co-morbid IHD have more breathlessness, lower exercise capacity and poorer health status.
V. Conclusion
In conclusion this study has shown that 19% of patients with proven CAD have concomitant COPD in a developing country-India. This will have enormous burden on health expenditure in a region where health budgets are already strained by costs of compacting endemic diseases. Given the projected increases in the incidence of CAD in this part of the world the problem is likely to get worse. The prevalence rate we recorded warrants routine screening of all CAD patients for COPD specially those with severe cardiac dysfunction, history of smoking and elderly population. Further large scale studies are needed to determine future trends and define the epidemiology of COPD better. 
